Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CAR-T immunotherapy

DRUG CLASS:

CAR-T immunotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

BCL6 rearrangement	Lymphoma	BCL6 rearrangement	Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
BCL2 rearrangement	Lymphoma	BCL2 rearrangement	Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3
GPC3 positive	Hepatocellular Cancer	GPC3 positive	Hepatocellular Cancer	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	CAR-T immunotherapy + dasatinib Sensitive: C3 – Early Trials CAR-T immunotherapy + dasatinib Sensitive : C3	CAR-T immunotherapy + dasatinib Sensitive: C3 – Early Trials CAR-T immunotherapy + dasatinib Sensitive : C3
ARID1A mutation	Non-Hodgkin’s Lymphoma	ARID1A mutation	Non-Hodgkin’s Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
TP53 mutation + ARID1A mutation	Non-Hodgkin’s Lymphoma	TP53 mutation + ARID1A mutation	Non-Hodgkin’s Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
B4GALNT1 expression	Retinoblastoma	B4GALNT1 expression	Retinoblastoma	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D
LY9 expression	Chronic Lymphocytic Leukemia	LY9 expression	Chronic Lymphocytic Leukemia	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D
MCAM expression	Solid Tumor	MCAM expression	Solid Tumor	AMT-253 Sensitive: D – Preclinical AMT-253 Sensitive : D	AMT-253 Sensitive: D – Preclinical AMT-253 Sensitive : D
MCAM expression	Melanoma	MCAM expression	Melanoma	AMT-253 Sensitive: D – Preclinical AMT-253 Sensitive : D	AMT-253 Sensitive: D – Preclinical AMT-253 Sensitive : D
HSPA5 overexpression	Brain Cancer	HSPA5 overexpression	Brain Cancer	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D
HSPA5 overexpression	Solid Tumor	HSPA5 overexpression	Solid Tumor	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D	CAR-T immunotherapy Sensitive: D – Preclinical CAR-T immunotherapy Sensitive : D